Self administered screening for hereditary cancers in conjunction with mammography and ultrasound

Familial Cancer

Volumn 12, Issue 4, 2013, Pages 651-656

  McDonnell, Charles H ^a   Seidenwurm, David J ^a   McDonnell, Diana E ^b   Bobolis, Kristie A ^c  

^a Radiological Associates of Sacramento Medical Group Inc   (United States)

^b SCRIPPS COLLEGE   (United States)

^c Capitol Hematology Oncology   (United States)

Author keywords

Cancer risk assessment; Familial cancers including breast cancer, ovarian cancer, colon cancer and endometrial cancer; Screening; Software

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; COMPUTER; COMPUTER PROGRAM; ENDOMETRIUM CANCER; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SELF EXAMINATION;

ADULT; COHORT STUDIES; EARLY DETECTION OF CANCER; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MAMMOGRAPHY; MIDDLE AGED; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PROGNOSIS; RISK FACTORS; SELF-ASSESSMENT; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY;

EID: 84888205000     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-013-9641-z     Document Type: Article

References (35)

1. Ford D et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676-689
2. Struewing JP et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408
3. Easton DF et al (1995) Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 56:265-271
4. Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA- mismatch-repair genes. Int J Cancer 81:214-218
5. Vasen F, Juul T et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020-1027
6. Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325
7. Warner E, Plewes DB, Shumak RS et al (2001) Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19:3524-3531
8. Kuhl CK, Schrading S, Leutner CC et al (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23(33):8469-8476
9. Stirling D, Evans DG, Pichert G et al (2005) Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gyne- cology and Obstetrics System. J Clin Oncol 23:5588-5596
10. Jacobs IJ, Mackay J, Menon U et al. (2006) Familial ovarian screening - effective or ineffective? Br J Cancer 95:1124; author reply 1126-7
11. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121:225-231
12. Calderon-Margalit R, Paltiel O (2004) Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 112:357-364
13. King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251-2256
14. Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261-269
15. Smith KL, Robson ME (2006) Update on hereditary breast cancer. Curr Oncol Rep 8(1):14-21
16. Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 84(1):16-28
17. Broaddus RR, Lu KH (2006) Women with HNPCC: a target population for the chemoprevention of gynecologic cancers. Front Biosci 11:2077-2080
18. Lu HK, Broaddus RR (2005) Gynecologic cancers in lynch syndrome/HNPCC. Fam Cancer 4(3):249-254
19. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, Lynch P, Burke W, Press N (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296(12):1507-1517
20. Ozanne EM, Loberg A, Hughes S et al (2009) Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. Breast J 15(2):155-162
21. Brian Drohan MS, Ozanne EA, Hughes KS (2009) Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. Breast J 15(1):46-55
22. Jones JL, Hughes KS, Kopans DB et al (2005) Evaluation of hereditary risk in a mammography population. Clin Breast Cancer 6(1):38-44
23. Dominguez FJ, Jones JL, Zabicki K et al (2005) Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population. Cancer 104(9):1849-1853
24. Hughes riskApps. Available www.hughesriskapps.com (first Accessed March 2007)
25. Saslow D et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75-89
26. Berry DA et al (1997) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89:227-238
27. Claus E, Risch N, Thompson W (1994) Autosomal dominant inheritance of early- onset breast cancer. Implications for risk prediction. Cancer 73:643-651
28. Tyrer J, Duffy S, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23:1111-1130
29. Myriad Genetic Laboratories, Inc. Available from URL: www.myriadpro.com (Accessed August 2006)
30. Chen S, Wang W, Lee S et al (2006) Colon cancer family registry. Prediction of germline mutations and cancer Rsk in the lynch syndrome. JAMA 296(12):1479-1487
31. NCCN GuidelinesTM, Version 1.2011, BSCR-A. Available www.nccn.org. Accessed April 2012
32. NCCN GuidelinesTM, Version 1.2011, HBOC-A1. Available www.nccn.org. Accessed April 2012
33. NCCN GuidelinesTM, Version 1.2012, LS-2. Available www.nccn.org. Accessed April 2012
34. Goss PE, Ingle JN, Ales-Martinez JE et al (2011) Exemestane for Breast-Cancer Prevention in Postmenopausal Women. N EnglJ Med 364:2381-2391
35. Domchek SM, Freibel TM, Singer CF et al (2010) Association of risk-reducing Surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967-975